Karyopharm Therapeutics (KPTI) closed the last trading session at $9.4, gaining 58% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $14.67 indicates a 56.1% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $5.32. While the lowest estimate of $6.00 indicates a 36.2% decline from the current price level, the most optimistic analys ...

Summary of Karyopharm Therapeutics Special Meeting Company Overview - **Company**: Karyopharm Therapeutics, Inc. (NasdaqGS: KPTI) - **Meeting Date**: February 18, 2026 - **Participants**: Richard Paulson (President, CEO, and Director), Michael Mano (Chief Legal Officer), Lori Macomber (Chief Financial Officer), Brendan Strong (Senior Vice President of Investor Relations) [1][2][3] Key Proposals Discussed 1. **Proposal One**: - Adoption and approval of an amendment to the restated certificate of incorporation to increase the number of authorized shares of capital stock from **58,333,333** to **111,000,000**. - Increase the number of authorized shares of common stock from **53,333,333** to **106,000,000** [7][9]. 2. **Proposal Two**: - Approval to adjourn the special meeting to a later date if necessary for further solicitation of proxies in case of insufficient votes for Proposal One [7][10]. Voting Results - A quorum was established with **18,310,283** shares of common stock entitled to vote present [5][6]. - Both proposals were approved based on preliminary voting results: - Proposal One to increase authorized shares was approved. - Proposal Two to allow for adjournment was also approved [9][10]. Important Notes - The meeting was conducted in a virtual format, allowing stockholders to participate similarly to an in-person meeting [2]. - Forward-looking statements were made, with a disclaimer regarding reliance on these statements due to potential differences in actual results [4]. - The final vote results will be documented in a Form 8-K to be filed within four business days after the meeting [10]. Additional Information - Stockholders were encouraged to submit questions related solely to the proposals during the meeting, but no questions were raised [7][8]. - The meeting concluded with gratitude expressed to shareholders for their participation and support [10].

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) KARYOPHARM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) (State or other jurisdicti ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $34.1 million, an increase of 11.8% compared to Q4 2024 [51] - For the full year 2025, total revenue was $146.1 million, a slight increase from 2024 [51] - U.S. XPOVIO net product revenue for Q4 2025 was $32.1 million, an increase of 9.6% compared to Q4 2024 [52] - For the full year, U.S. XPOVIO net product revenue was $114.9 million, an increase of 1.9% from 2024 [52] - The company reported a net loss of $102.2 million, or $5.71 per share on a GAAP basis in Q4 2025 [60] - The full year net loss was $196 million, or $17.93 per diluted share for 2025 [60] Business Line Data and Key Metrics Changes - Xpovio net product revenue grew to $32.1 million in Q4 2025 and $114.9 million for the full year 2025 [36] - The company expects to guide towards $115 to $130 million of Xpovio net product revenue in 2026 [36] - License and other revenue was $2 million in Q4 and $31.2 million for the full year 2025 [53] Market Data and Key Metrics Changes - Demand for Xpovio was consistent year-over-year in 2025, with the community setting driving approximately 60% of total U.S. sales [37] - The company is targeting approximately 4,000 newly diagnosed patients with intermediate to high-risk myelofibrosis [45] Company Strategy and Development Direction - Karyopharm is focused on expanding its oncology franchise, particularly in myelofibrosis and endometrial cancer [7][8] - The company is preparing for pivotal data readouts from its late-stage clinical programs, with significant opportunities in myelofibrosis and endometrial cancer [63] - The strategy includes evaluating a range of financing and strategic options to maintain flexibility and align capital decisions with value creation [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming data readout from the phase three SENTRY trial in March, which is expected to address an unmet need in myelofibrosis [9][26] - The company is managing its business with discipline, focusing on near-term value-creating milestones while maintaining flexibility [64] - Management emphasized the importance of executing well and generating high-quality data to define the next phase of the company [64] Other Important Information - The company ended the year with $64.1 million in cash, cash equivalents, restricted cash, and investments, compared to $109.1 million as of December 31, 2024 [61] - The full year 2025 included $15 million of R&D reimbursement from Menarini, which will not be received in future years [53] Q&A Session Summary Question: Can you discuss the differences in exposure and activity between the 40 mg and 60 mg doses? - Management indicated that the 60 mg dose showed a clear benefit-risk profile compared to the 40 mg dose, with maximized efficacy in the 60 mg group [70] Question: What are your thoughts on Novartis' recent plans in myelofibrosis? - Management noted that the continued investment in the myelofibrosis space highlights the unmet need and significant market value [74] Question: Can you elaborate on the strategy for eltanexor and other MPNs? - Management stated that eltanexor is a second-generation XPO1 inhibitor with potential applications beyond myelofibrosis, including other MPNs [78] Question: What updates can you provide on the blinded safety data? - Management confirmed that no updates have been made beyond previously disclosed data, and they are looking forward to the upcoming data readout [85] Question: How do you view the potential for symptomatic improvement in your trials? - Management emphasized the goal of achieving statistical significance for both spleen volume reduction and symptomatic improvement [104]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $34.1 million, an increase of 11.8% compared to Q4 2024. For the full year, total revenue was $146.1 million, a slight increase from 2024 [50]. - U.S. XPOVIO net product revenue for Q4 2025 was $32.1 million, an increase of 9.6% compared to Q4 2024. For the full year, it was $114.9 million, an increase of 1.9% from 2024 [51]. - The company reported a net loss of $102.2 million, or $5.71 per share for Q4 2025, and a net loss of $196 million, or $17.93 per diluted share for the full year 2025 [59]. Business Line Data and Key Metrics Changes - Xpovio net product revenue grew to $32.1 million in Q4 2025 and $114.9 million for the full year 2025, with expectations to reach $115 million-$130 million in 2026 [35]. - License and other revenue was $2 million in Q4 and $31.2 million for the full year 2025, including $15 million of R&D reimbursement from Menarini, which will not continue in 2026 [52]. Market Data and Key Metrics Changes - Demand for Xpovio remained consistent year-over-year in 2025, with the community setting driving approximately 60% of total U.S. sales [36]. - The U.S. market for myelofibrosis includes approximately 20,000 patients, representing a multibillion-dollar marketplace, with about 6,000 newly diagnosed patients each year [43]. Company Strategy and Development Direction - The company aims to expand its oncology franchise, focusing on myelofibrosis and endometrial cancer as key growth areas [6][7]. - Karyopharm is preparing for pivotal data readouts from late-stage clinical programs, with the SENTRI trial for myelofibrosis data expected in March 2026 and the EXPORT EC042 trial for endometrial cancer data expected in mid-2026 [8][9]. Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of optimizing clinical programs and maintaining a disciplined approach to capital allocation [63]. - The company is focused on executing well, generating high-quality data, and allowing these results to define the next phase of the company [63]. Other Important Information - The company ended the year with $64.1 million in cash and equivalents, down from $109.1 million at the end of 2024 [60]. - Research and development expenses for Q4 2025 were $27.7 million, a decrease of 17% from Q4 2024, reflecting cost reduction initiatives [53]. Q&A Session Summary Question: Can you discuss the differences in exposure and activity between the 40 mg and 60 mg doses? - Management noted that the 60 mg dose showed a clear benefit-risk profile favoring efficacy and safety compared to the 40 mg dose [68]. Question: What are your thoughts on Novartis' recent plans in myelofibrosis? - Management highlighted the importance of targeting the right patient population and expressed confidence in establishing their product as the standard of care pending positive data [72][75]. Question: Can you elaborate on the strategy for eltanexor and other MPNs if myelofibrosis data is positive? - Management indicated that eltanexor, a second-generation XPO1 inhibitor, has potential in other MPNs and is looking to expand beyond myelofibrosis [78]. Question: What updates can you provide on the blinded safety data and discontinuation rates? - Management confirmed that no updates have been made beyond previously disclosed data, but they are optimistic about the upcoming data readout [84]. Question: What is the expected threshold for symptomatic improvement in the upcoming trials? - Management aims for statistical significance in both spleen volume reduction and symptomatic improvement, emphasizing the importance of both metrics in their analysis plan [103].

Karyopharm Therapeutics (NasdaqGS:KPTI) Q4 2025 Earnings call February 12, 2026 08:00 AM ET Speaker6Good morning. My name is Ludy, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics fourth quarter and full year 2025 financial results conference call. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Brandon Strong ...

Fourth Quarter 2025 Financial Results & Business Update February 12, 2026 On Today's Call • Welcome Brendan Strong, SVP, Investor Relations • Overview Richard Paulson, President and Chief Executive Officer • Pipeline Update Dr. Reshma Rangwala, Chief Medical Officer and Head of Research • Commercial Highlights and Myelofibrosis Commercial Opportunity Sohanya Cheng, Chief Commercial Officer and Head of Business Development • Financial Results and Guidance Lori Macomber, Chief Financial Officer and Treasurer ...

Core Insights - Karyopharm Therapeutics reported its financial results for Q4 and full year 2025, highlighting significant revenue growth and upcoming clinical milestones for its lead product, XPOVIO (selinexor) [1][2] Financial Performance - Total revenue for Q4 2025 was $34.1 million, up from $30.5 million in Q4 2024, while full-year revenue reached $146.1 million compared to $145.2 million in 2024 [2][5] - U.S. net product revenue for XPOVIO was $32.1 million in Q4 2025, compared to $29.3 million in Q4 2024, and $114.9 million for the full year, up from $112.8 million in 2024 [2][5] - The company expects total revenue for 2026 to be between $130 million and $150 million, with U.S. XPOVIO net product revenue projected between $115 million and $130 million [1][2] Research and Development Highlights - The Phase 3 SENTRY trial for myelofibrosis is expected to report top-line data in March 2026, with the potential to introduce the first combination therapy in this area [1][3] - The Phase 3 XPORT-EC-042 trial for endometrial cancer is on track to report top-line data in mid-2026, focusing on a biomarker-driven patient population [1][3] - Enrollment in the Phase 3 XPORT-MM-031 trial for multiple myeloma was completed in Q4 2024, with top-line data anticipated in the second half of 2026 [1][3] Operational Objectives - The company aims to maintain its commercial foundation in the competitive multiple myeloma market and drive increased revenues for XPOVIO [2][3] - Karyopharm plans to support global launches of XPOVIO in ex-U.S. territories following regulatory approvals [2][3] Market Context - Myelofibrosis affects approximately 20,000 patients in the U.S., with significant unmet needs in treatment options [3] - Endometrial cancer is the most common gynecologic malignancy in the U.S., with rising incidence and mortality rates, highlighting the need for effective therapies [3][4]

Core Viewpoint - Karyopharm Therapeutics Inc. will report its fourth quarter and full year 2025 financial results on February 12, 2026, and will host a conference call to discuss these results and other updates [1]. Company Overview - Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies, particularly through oral compounds that address nuclear export dysregulation, a key mechanism in oncogenesis [3]. - The company's lead compound, XPOVIO (selinexor), is a first-in-class oral exportin 1 (XPO1) inhibitor approved in the U.S. for three oncology indications and has received regulatory approvals in over 50 territories, including the EU, UK (as NEXPOVIO), and China [3]. - Karyopharm has a focused pipeline targeting high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL) [3].

Financial Projections - Preliminary unaudited total revenue for full year 2025 is expected to be approximately $145 million, with U.S. XPOVIO net product revenue estimated at $115 million[1][4][8]. - Cash and cash equivalents as of December 31, 2025, were approximately $64 million, expected to fund operations into Q2 2026[8]. - The company is currently evaluating its preliminary financial information for Q4 and full year 2025, including expected cash runway and liquidity[28]. Clinical Trials and Research - The Phase 3 SENTRY trial in myelofibrosis completed enrollment with 353 patients, evaluating selinexor in combination with ruxolitinib[3][13]. - Top-line data from the Phase 3 SENTRY trial is expected in March 2026, which could redefine the standard-of-care in myelofibrosis[2][14]. - The Phase 3 XPORT-EC-042 trial in endometrial cancer is on track to report top-line data in mid-2026, focusing on a targeted patient population[2][10]. - The company modified the design of the Phase 3 XPORT-EC-042 trial to focus on patients with proficient and deficient mismatch repair status, increasing the sample size to approximately 276 patients[8][18]. Product and Market Development - Demand for XPOVIO remained consistent in 2025 compared to 2024, with approximately 60% of overall net product revenue driven by the community setting[4]. - Global patient access for selinexor expanded in 2025, with approvals in over 50 countries, including favorable reimbursement decisions in Spain and China[4]. - Karyopharm Therapeutics' lead compound, XPOVIO® (selinexor), is approved in the U.S. and marketed in three oncology indications, with regulatory approvals in over 50 territories including the EU and China[27]. Safety and Adverse Reactions - In the BOSTON trial, 6% of patients experienced fatal adverse reactions within 30 days of the last treatment, while serious adverse reactions occurred in 52% of patients[26]. - The treatment discontinuation rate due to adverse reactions in the BOSTON trial was 19%[26]. - In the STORM trial, 9% of patients experienced fatal adverse reactions, with serious adverse reactions occurring in 58% of patients[26]. - The discontinuation rate due to adverse reactions in the STORM trial was 27%[26]. - In the SADAL trial, fatal adverse reactions occurred in 3.7% of patients within 30 days and 5% within 60 days, with serious adverse reactions occurring in 46% of patients[26]. Strategic Outlook - Karyopharm anticipates 2026 to be a catalyst-rich year with significant opportunities for long-term value creation[2]. - The company completed strategic financing transactions to extend cash runway beyond the expected top-line readout of the Phase 3 SENTRY trial[8]. - Management emphasizes the importance of regulatory approvals and successful commercialization of XPOVIO and other drug candidates[29]. - Karyopharm is focused on developing therapies for multiple high unmet need cancers, including multiple myeloma and diffuse large B-cell lymphoma (DLBCL)[27]. Risks and Uncertainties - Karyopharm's forward-looking statements are subject to numerous risks and uncertainties that may cause actual results to differ materially from current expectations[28].